Margetuximab - MacroGenics

Drug Profile

Margetuximab - MacroGenics

Alternative Names: Anti-HER2-monoclonal-antibody- GC Pharma; MGAH-22

Latest Information Update: 07 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Raven biotechnologies
  • Developer GC Pharma; Green Cross; MacroGenics; Merck Sharp & Dohme
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase I/II Gastric cancer
  • Discontinued Bladder cancer; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 23 Jan 2018 Margetuximab receives Fast Track designation for Breast cancer [IV,Infusion] (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA
  • 23 Jan 2018 Discontinued - Phase-I for Bladder cancer in USA, South Korea (IV)
  • 23 Jan 2018 Discontinued - Phase-I for Non-small cell lung cancer in USA, South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top